Best for
Mobile
How to buy Celgene Corporation shares
Own Celgene Corporation shares in just a few minutes. Share price changes are updated daily.
Fact checked
Celgene Corporation (CELG) is a leading drug manufacturers-general business based in the US. Celgene Corporation is listed on the NASDAQ and employs 8,852 staff. All prices are listed in US Dollars.
How to buy shares in Celgene Corporation
- Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: CELG in this case.
- Research Celgene Corporation shares. The platform should provide the latest information available.
- Buy your Celgene Corporation shares. It's that simple.
What's in this guide?
- Can I buy shares in Celgene Corporation?
- Celgene Corporation shares summary
- Compare share dealing platforms
- Is Celgene Corporation stock a buy or sell?
- Can I short Celgene Corporation shares?
- Is Celgene Corporation suitable for ethical investing?
- Are Celgene Corporation shares over-valued?
- Celgene Corporation's financials
- How volatile are Celgene Corporation shares?
- Does Celgene Corporation pay a dividend?
- Have Celgene Corporation shares ever split?
- Other common questions
Celgene Corporation share price
Use our graph to track the performance of CELG stocks over time.Celgene Corporation shares at a glance
Information last updated 2020-04-13.
| 52-week range | $0 - $0 |
|---|---|
| 50-day moving average | $108.24 |
| 200-day moving average | $104.3553 |
| Wall St. target price | $103.4 |
| PE ratio | 13.33 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $8.133 |
Invest in Celgene Corporation shares with 0% commission
Other fees may apply. Your capital is at risk.
- Unlimited trades, with no dealing charges or management fees
- If your trades get copied you can earn extra money
- Create an account today in a few minutes
Go to site
Capital at risk
Share dealing platform comparison
Table: sorted by promoted deals first
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Is it a good time to buy Celgene Corporation stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is Celgene Corporation under- or over-valued?
Valuing Celgene Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Celgene Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Celgene Corporation's P/E ratio
Celgene Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, Celgene Corporation shares trade at around 13x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Celgene Corporation's PEG ratio
Celgene Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.86. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Celgene Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Celgene Corporation's EBITDA
Celgene Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $8.9 billion.
The EBITDA is a measure of a Celgene Corporation's overall financial performance and is widely used to measure a its profitability.
Celgene Corporation financials
| Revenue TTM | $17 billion |
|---|---|
| Operating margin TTM | 48.75% |
| Gross profit TTM | $14.1 billion |
| Return on assets TTM | 13.69% |
| Return on equity TTM | 69.39% |
| Profit margin | 34.63% |
| Book value | $16.99 |
| Market capitalisation | $77 billion |
TTM: trailing 12 months
How to short and sell Celgene Corporation shares
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "CELG.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 12.0 million Celgene Corporation shares held short by investors – that's known as Celgene Corporation's "short interest". This figure is 4.8% down from 12.6 million last month.
There are a few different ways that this level of interest in shorting Celgene Corporation shares can be evaluated.
Celgene Corporation's "short interest ratio" (SIR)
Celgene Corporation's "short interest ratio" (SIR) is the quantity of Celgene Corporation shares currently shorted divided by the average quantity of Celgene Corporation shares traded daily (recently around 3.5 million). Celgene Corporation's SIR currently stands at 3.45. In other words for every 100,000 Celgene Corporation shares traded daily on the market, roughly 3450 shares are currently held short.
However Celgene Corporation's short interest can also be evaluated against the total number of Celgene Corporation shares, or, against the total number of tradable Celgene Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Celgene Corporation's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Celgene Corporation shares in existence, roughly 20 shares are currently held short) or 0.0185% of the tradable shares (for every 100,000 tradable Celgene Corporation shares, roughly 19 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Celgene Corporation.
Find out more about how you can short Celgene Corporation stock.
Celgene Corporation's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Celgene Corporation.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Celgene Corporation's total ESG risk score
Total ESG risk: 23.71
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Celgene Corporation's overall score of 23.71 (as at 01/01/2019) is excellent – landing it in it in the 3rd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Celgene Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Celgene Corporation's environmental score
Environmental score: 1.02/100
Celgene Corporation's environmental score of 1.02 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Celgene Corporation is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Celgene Corporation's social score
Social score: 14.4/100
Celgene Corporation's social score of 14.4 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Celgene Corporation is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Celgene Corporation's governance score
Governance score: 5.29/100
Celgene Corporation's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Celgene Corporation is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Celgene Corporation's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Celgene Corporation scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Celgene Corporation has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Celgene Corporation was last rated for ESG on: 2019-01-01.
| Total ESG score | 23.71 |
|---|---|
| Total ESG percentile | 2.75 |
| Environmental score | 1.02 |
| Environmental score percentile | 2 |
| Social score | 14.4 |
| Social score percentile | 2 |
| Governance score | 5.29 |
| Governance score percentile | 2 |
| Level of controversy | 2 |
Celgene Corporation share dividends
We're not expecting Celgene Corporation to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Have Celgene Corporation's shares ever split?
Celgene Corporation's shares were split on a 2:1 basis on 26 June 2014. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Celgene Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Celgene Corporation shares which in turn could have impacted Celgene Corporation's share price.
Celgene Corporation share price volatility
Over the last 12 months, Celgene Corporation's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Celgene Corporation's is 1.4131. This would suggest that Celgene Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Win £500 to get your trading started
Subscribe to trending stock alerts for a chance to win
Celgene Corporation overview
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; bluebird bio, Inc.; Lycera Corp.; Juno Therapeutics, Inc.; EXSCIENTIA LTD.; and IMIDomics SL, as well as immuno-oncology collaboration with Sutro Biopharma. The company also has strategic collaboration with Skyhawk Therapeutics, Inc. to discover and develop novel small molecules that modulate RNA splicing. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey. As of November 20, 2019, Celgene Corporation operates as a subsidiary of Bristol-Myers Squibb Company.
Frequently asked questions
More guides on Finder
-
How to buy Transportation and Logistics Systems shares
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Charlie’s Holdings shares
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Lemonade shares
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Unity Software shares
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
-
How to buy FuelCell Energy shares
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
-
How to buy CloudCommerce shares
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
-
How to buy Zomedica Pharmaceuticals shares
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
-
How to buy YRC Worldwide shares
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
-
How to buy Xeros Technology Group shares
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
-
How to buy Xpediator shares
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
Ask an Expert